Retatrutide
GZBF
Eli Lilly · Phase 2 · Recruiting · Enrollment 300
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Retatrutide (LY3437943) 1 mg once weekly (no escalation) | n/r | n/r | n/r | n/r |
| Retatrutide 4 mg once weekly, escalation subgroup (a): 2 mg → 4 mg. | n/r | n/r | n/r | n/r |
| Retatrutide 4 mg once weekly, subgroup (b): start 4 mg (no escalation). | n/r | n/r | n/r | n/r |
| Retatrutide 8 mg once weekly, subgroup (a): 2 mg → 4 mg → 8 mg | n/r | n/r | n/r | n/r |
| Retatrutide 12 mg once weekly: 2 mg → 4 mg → 8 mg → 12 mg. | n/r | n/r | n/r | n/r |
| Placebo once weekly (matched escalation schedule to maintain blinding). | n/r | n/r | n/r | n/r |
| Retatrutide 8 mg once weekly, subgroup (b): 4 mg → 8 mg. | n/r | n/r | n/r | n/r |
Not shown
- Retatrutide (LY3437943) 1 mg once weekly (no escalation): endpoint not reported
- Retatrutide 4 mg once weekly, escalation subgroup (a): 2 mg → 4 mg.: endpoint not reported
- Retatrutide 4 mg once weekly, subgroup (b): start 4 mg (no escalation).: endpoint not reported
- Retatrutide 8 mg once weekly, subgroup (a): 2 mg → 4 mg → 8 mg: endpoint not reported
- Retatrutide 12 mg once weekly: 2 mg → 4 mg → 8 mg → 12 mg.: endpoint not reported
- Placebo once weekly (matched escalation schedule to maintain blinding).: endpoint not reported
- Retatrutide 8 mg once weekly, subgroup (b): 4 mg → 8 mg.: endpoint not reported